{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:57:27Z","timestamp":1761897447691,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Key Project of Zhenjiang City for Health Science and Technology","award":["SH2016038 and SH2019046"],"award-info":[{"award-number":["SH2016038 and SH2019046"]}]},{"name":"The Project of Young Medical Talents in Jiangsu Province","award":["QNRC2016829"],"award-info":[{"award-number":["QNRC2016829"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In addition to ovarian and breast cancers, loss-of-function mutations in <jats:italic>BRCA1<\/jats:italic> and <jats:italic>BRCA2<\/jats:italic> genes are also linked to an increased risk of pancreatic cancer, with ~\u20094 to 7% of pancreatic cancer patients harboring germline <jats:italic>BRCA<\/jats:italic> mutations. Most <jats:italic>BRCA<\/jats:italic> alterations in pancreatic cancer are frame-shifting indels, stop-gain, and splice-site mutations, but single nucleotide substitutions are rare. Recent studies demonstrated a significant progression-free survival (PFS) benefit from maintenance olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor administered to patients with germline <jats:italic>BRCA<\/jats:italic> mutations and metastatic pancreatic cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>Here, we report a metastatic pancreatic cancer case who harbored a novel somatic <jats:italic>BRCA2<\/jats:italic> c.6944T\u2009&gt;\u2009C (p. I2315T) point mutation. After 6\u00a0weeks first-line chemotherapy, the patient was refractory to treatment and had a progressive disease. Due to the novel nonsynonymous <jats:italic>BRCA2<\/jats:italic> point mutation, we decided to change the strategy by administering olaparib. The patient benefited from olaparib therapy and achieved a PFS of ~\u20096.5\u00a0months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We describe a patient carrying a novel somatic <jats:italic>BRCA2<\/jats:italic> p. I2315T point mutation, which is first reported in metastatic pancreatic cancer. This case report indicates that a gene mutation-based strategy should be considered in the clinic to provide more effective treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12920-020-00850-6","type":"journal-article","created":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T16:08:06Z","timestamp":1609949286000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A novel somatic BRCA2 point mutation in a metastatic pancreatic cancer patient: a case report"],"prefix":"10.1186","volume":"14","author":[{"given":"Deqiang","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruting","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sisi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3762-9817","authenticated-orcid":false,"given":"Xiaoqin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,6]]},"reference":[{"key":"850_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1053\/j.seminoncol.2018.12.003","volume":"46","author":"M Ducreux","year":"2019","unstructured":"Ducreux M, Seufferlein T, Van Laethem JL, et al. Systemic treatment of pancreatic cancer revisited. Semin Oncol. 2019;46:28\u201338.","journal-title":"Semin Oncol"},{"key":"850_CR2","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.7150\/jca.30410","volume":"10","author":"I Gorodetska","year":"2019","unstructured":"Gorodetska I, Kozeretska I, Dubrovska A. BRCA genes: the role in genome stability, cancer stemness and therapy Resistance. J Cancer. 2019;10:2109\u201327.","journal-title":"J Cancer"},{"key":"850_CR3","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1093\/hmg\/10.7.705","volume":"10","author":"PL Welcsh","year":"2001","unstructured":"Welcsh PL, King MC. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet. 2001;10:705\u201313.","journal-title":"Hum Mol Genet"},{"key":"850_CR4","doi-asserted-by":"publisher","first-page":"10778","DOI":"10.3748\/wjg.v20.i31.10778","volume":"20","author":"P Ghiorzo","year":"2014","unstructured":"Ghiorzo P. Genetic predisposition to pancreatic cancer. World J Gastroenterol. 2014;20:10778\u201389.","journal-title":"World J Gastroenterol"},{"issue":"28","key":"850_CR5","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1200\/JCO.2014.59.7401","volume":"33","author":"S Holter","year":"2015","unstructured":"Holter S, Borgida A, Dodd A, et al. Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J Clin Oncol. 2015;33(28):3124\u20139.","journal-title":"J Clin Oncol"},{"key":"850_CR6","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3390\/cancers10120487","volume":"10","author":"I Faraoni","year":"2018","unstructured":"Faraoni I, Graziani G. Role of BRCA mutations in cancer treatment with poly(ADP-ribose) polymerase (PARP) inhibitors. Cancers. 2018;10:487.","journal-title":"Cancers"},{"key":"850_CR7","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317\u201327.","journal-title":"N Engl J Med"},{"key":"850_CR8","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1093\/annonc\/mdz406","volume":"30","author":"P Hammel","year":"2019","unstructured":"Hammel P, Kindler HL, Reni M, et al. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. Ann Oncol. 2019;30:1959\u201368.","journal-title":"Ann Oncol"},{"key":"850_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","volume":"19","author":"H Li","year":"2020","unstructured":"Li H, Liu Z-Y, Wu N, et al. PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol Cancer. 2020;19:107\u2013107.","journal-title":"Mol Cancer"},{"key":"850_CR10","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im S-A, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523\u201333.","journal-title":"N Engl J Med"},{"key":"850_CR11","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379:2495\u2013505.","journal-title":"N Engl J Med"},{"key":"850_CR12","first-page":"1869304","volume":"2016","author":"J Martinez-Useros","year":"2016","unstructured":"Martinez-Useros J, Garcia-Foncillas J. The role of BRCA2 mutation status as diagnostic, predictive, and prognosis biomarker for pancreatic cancer. Biomed Res Int. 2016;2016:1869304.","journal-title":"Biomed Res Int"},{"key":"850_CR13","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41436-018-0052-2","volume":"21","author":"RLS Mesman","year":"2019","unstructured":"Mesman RLS, Calleja F, Hendriks G, et al. The functional impact of variants of uncertain significance in BRCA2. Genet Med. 2019;21:293\u2013302.","journal-title":"Genet Med"},{"key":"850_CR14","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1007\/s12032-012-0294-9","volume":"29","author":"A Juwle","year":"2012","unstructured":"Juwle A, Saranath D. BRCA1\/BRCA2 gene mutations\/SNPs and BRCA1 haplotypes in early-onset breast cancer patients of Indian ethnicity. Med Oncol. 2012;29:3272\u201381.","journal-title":"Med Oncol"},{"key":"850_CR15","doi-asserted-by":"publisher","first-page":"E1200","DOI":"10.1002\/humu.21202","volume":"31","author":"A Borg","year":"2010","unstructured":"Borg A, Haile RW, Malone KE, et al. Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study. Hum Mutat. 2010;31:E1200\u201340.","journal-title":"Hum Mutat"},{"key":"850_CR16","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/nsmb.2899","volume":"21","author":"T Shahid","year":"2014","unstructured":"Shahid T, Soroka J, Kong E, et al. Structure and mechanism of action of the BRCA2 breast cancer tumor suppressor. Nat Struct Mol Biol. 2014;21:962\u20138.","journal-title":"Nat Struct Mol Biol"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-020-00850-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12920-020-00850-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-020-00850-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T16:37:47Z","timestamp":1609951067000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-020-00850-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,6]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["850"],"URL":"https:\/\/doi.org\/10.1186\/s12920-020-00850-6","relation":{},"ISSN":["1755-8794"],"issn-type":[{"type":"electronic","value":"1755-8794"}],"subject":[],"published":{"date-parts":[[2021,1,6]]},"assertion":[{"value":"20 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the ethical committee of the Affiliated Hospital of Jiangsu University. Written informed consent was provided by the patient.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of the case and all accompanying tables\/images. A copy of the written consent is available for review by the Editor of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Ruting Guan and Sisi Liu are the employees of Nanjing Geneseeq Technology Inc., China; Man Yu is an employee of Geneseeq Technology Inc., Canada. The remaining authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}